Ligand-Based Drug Design vs De Novo Drug Design
Developers should learn LBDD when working in pharmaceutical, biotech, or academic research settings to accelerate early-stage drug discovery by predicting the activity of new compounds without requiring detailed protein structural data meets developers should learn de novo drug design when working in pharmaceutical research, bioinformatics, or computational chemistry to create innovative therapeutics for diseases with limited treatment options. Here's our take.
Ligand-Based Drug Design
Developers should learn LBDD when working in pharmaceutical, biotech, or academic research settings to accelerate early-stage drug discovery by predicting the activity of new compounds without requiring detailed protein structural data
Ligand-Based Drug Design
Nice PickDevelopers should learn LBDD when working in pharmaceutical, biotech, or academic research settings to accelerate early-stage drug discovery by predicting the activity of new compounds without requiring detailed protein structural data
Pros
- +It is essential for virtual screening, lead optimization, and identifying novel drug candidates in projects targeting diseases like cancer, infectious diseases, or neurological disorders
- +Related to: quantitative-structure-activity-relationship, pharmacophore-modeling
Cons
- -Specific tradeoffs depend on your use case
De Novo Drug Design
Developers should learn De Novo Drug Design when working in pharmaceutical research, bioinformatics, or computational chemistry to create innovative therapeutics for diseases with limited treatment options
Pros
- +It is particularly useful for targeting novel proteins, optimizing lead compounds, or designing molecules with specific ADMET (absorption, distribution, metabolism, excretion, toxicity) profiles
- +Related to: computational-chemistry, machine-learning
Cons
- -Specific tradeoffs depend on your use case
The Verdict
Use Ligand-Based Drug Design if: You want it is essential for virtual screening, lead optimization, and identifying novel drug candidates in projects targeting diseases like cancer, infectious diseases, or neurological disorders and can live with specific tradeoffs depend on your use case.
Use De Novo Drug Design if: You prioritize it is particularly useful for targeting novel proteins, optimizing lead compounds, or designing molecules with specific admet (absorption, distribution, metabolism, excretion, toxicity) profiles over what Ligand-Based Drug Design offers.
Developers should learn LBDD when working in pharmaceutical, biotech, or academic research settings to accelerate early-stage drug discovery by predicting the activity of new compounds without requiring detailed protein structural data
Disagree with our pick? nice@nicepick.dev